Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 135 resultados

DEFLAMMATION: Negative Regulation of Inflammatory Responses Revealed with Camelid Nanobodies UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2023-COG The innate immune system evokes inflammation to control pathogens or damage. Sophisticated mechanisms interpret molecular triggers to activa...
2024-09-01 - 2029-08-31 | Financiado

DEFLAMMATION: Negative Regulation of Inflammatory Responses Revealed with Camelid Nanobodies UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2023-COG The innate immune system evokes inflammation to control pathogens or damage. Sophisticated mechanisms interpret molecular triggers to activa...
2024-08-28 - 2029-08-31 | Financiado

BATOFF: Turning off the furnace: the intracellular brake systems for brown fat thermogenesis UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2022-STG Free-ranging animals are continuously exposed to fluctuating ambient temperature, therefore rapid fine-tuning of thermogenesis to maintain c...
2024-01-01 - 2028-12-31 | Financiado

NalpACT: Exploring inflammasome activation and targeted inhibition UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2022-ADG Inflammasomes are cytosolic multi-protein complexes that form in response to a wide range of pathogens, tissue damage, and other harmful sti...
2024-01-01 - 2028-12-31 | Financiado

TempCOdE: Temporally complex odour information encoding UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2022-STG A fundamental challenge for the brain is to extract relevant information from an ever changing external world. Natural odours are in a const...
2023-08-01 - 2028-07-31 | Financiado

UNBIAS: Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation. UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2023-POC "With a growing ageing population, there is an imminent demand to develop new therapeutic strategies to ameliorate disorders of the hematopo...
2023-08-01 - 2025-01-31 | Financiado

EndoRPHIm: Endogenous Retroelements As Transcriptional Parasites And Modulators Of Host Immunity UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2021-COG Almost half of our genome is occupied by ancient viral sequences that can be mobilized under certain conditions and either jump or copy them...
2023-06-01 - 2028-05-31 | Financiado

AI-POD: Trustworthy AI Tools for the Prediction of Obesity Related Vascular Diseases UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-01-two-stage Weight problems and obesity are increasing at a rapid rate already concerning more than 436mio people in European countries. Obese persons h...
2023-05-01 - 2027-04-30 | Financiado

eWHORM: Enabling the WHO-Roadmap 2030 UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2022-01 We will establish for the first time in NTDs an adaptive clinical trial platform and improve clinical research infrastructure in four SSA co...
2023-04-01 - 2028-03-31 | Financiado

REPRESSIT: REPRESSIT: A novel class of clinical immune checkpoint inhibitors UNIVERSITATSKLINIKUM BONN participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 In the tumor microenvironment, continuous or tonic stimulation of T cells induces checkpoint signaling through inhibitory immune receptors (...
2023-03-13 - 2028-04-30 | Financiado

eWHORM: Enabling the WHO-Roadmap 2030 UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2022-01 We will establish for the first time in NTDs an adaptive clinical trial platform and improve clinical research infrastructure in four SSA co...
2023-03-02 - 2028-03-31 | Financiado

FIREALARM: Inflammatory signals of cell death UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2021-COG Inflammation is a natural mechanism to restore tissue homeostasis, and its deregulation causes human disease. The programmed cell death form...
2023-01-01 - 2027-12-31 | Financiado

PREVENTABLE: CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE UNIVERSITATSKLINIKUM BONN participó en un HORIZON EUROPE: HORIZON-HLTH-2022-CARE-08 Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS...
2022-12-02 - 2025-12-31 | Financiado

LipidGlia: Exposing the glial metabolism - common link to brain damage UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 European population is rapidly aging. While it was commonly believed that brain aging leads to neuronal loss, recent studies found that inst...
2022-10-04 - 2025-06-30 | Financiado

PhotoTherEpi: Targeting epilepsy with phototherapeutics UNIVERSITATSKLINIKUM BONN tramitó un HORIZON EUROPE: ERC-2021-STG As photo-activatable drugs (PDs) can be precisely controlled in space and time, caged and switchable photoactivatable drugs (CPDs, SPDs) are...
2022-09-01 - 2027-08-31 | Financiado

environMENTAL: Reducing the impact of major environmental challenges on mental health The environMENTAL project will investigate how some of the greatest global environmental challenges, climate change, urbanisation, and psych...
2022-05-23 - 2027-05-31 | Financiado

PAL-CYCLES: PALliative Care Yields Cancer welLbEing Support UNIVERSITATSKLINIKUM BONN participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 Challenge: many patients with advanced cancer in the final phase of life leave the hospital without continuity of information, and certainty...
2022-05-18 - 2027-08-31 | Financiado

UKB